


# Disclosures

- Grant funding
  - Centers for Disease Control and Prevention
  - Agency for Healthcare Research and Quality
  - Massachusetts Department of Public Health
- Royalties
  - UpToDate for chapters on pneumonia


## Outline

- How accurate are clinical signs for pneumonia?
- Is pneumonia in hospitalized patients viral or bacterial?
- What kind of imaging should we get?
- Is there a role for procalcitonin?
- Do we need to get cultures?
- Do we need to start antibiotics right away?
- o What should we treat with?
- Do we need to include atypical coverage?
- o How long should we treat for?

## AMERICAN THORACIC SOCIETY Released in DOCUMENT 2019 **Diagnosis and Treatment of Adults with Community-acquired Pneumonia** An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America A Joshua P. Metlay\*, Grant W. Waterer\*, Ann C. Long, Antonio Anzueto, Jan Brozek, Kristina Crothers, Laura A. Cooley, Nathan C. Dean, Michael J. Fine, Scott A. Flanders, Marie R. Griffin, Mark L. Metersky, Daniel M. Musher, Marcos I. Restrepo, and Cynthia G. Whitney; on behalf of the American Thoracic Society and Infectious Diseases Society of America This official clinical practice guideline was approved by the American Thoracic Society May 2019 and the Infectious Diseases Society of America AUGUST 2019 Background: This document provides evidence-based clinical management decisions. Although some recommendations remain practice guidelines on the management of adult patients with unchanged from the 2007 guideline, the availability of results from community-acquired pneumonia. new therapeutic trials and epidemiological investigations led to








# Would you start antibiotics?\*


A. Yes


B. No


# Why is Pneumonia So Difficult to Diagnose? Many medical conditions in hospitalized patients present with the same clinical signs as pneumonia Radiographic opacities Fever Abnormal white blood cell count Impaired oxygenation Increased pulmonary secretions




Analysis of 17,290 pat Inappropriate diagnosis defined		0 1	•	
Measure	AOR (95% CI)	Inappropriate diagnosis less likely	Inappropriate diagnosis more likely	P value
Dementia	1.79 (1.55-2.08)		<b>_</b>	<.001
Altered mental status, no dementia	1.75 (1.39-2.19)			<.001
Age, per 10 y	1.08 (1.05-1.11)		•	<.001
Home oxygen	0.87 (0.77-1.00)			.04
Chronic kidney disease	0.87 (0.76-0.99)			.03
Respiratory viral panel negative	0.88 (0.75-1.03)			.11
Respiratory viral panel positive	0.80 (0.66-0.98)			.03
≥2 SIRS criteria plus end organ dysfunction	0.77 (0.70-0.84)	-		<.001
History of pulmonary cancer	0.68 (0.53-0.88)			.003
		0 0.5 1	.0 1.5 2.0	














Etiology of Community-Acq 2,259 adults admitted to 5 hospitals in 0		
Rhinovirus	8.6%	
Influenza	5.8%	
Strep. pneumoniae	5.1%	
Metapneumovirus	3.9%	
RSV	3.0%	
Parainfluenza	3.0%	
Coronavirus	2.3%	
Mycoplasma pneumoniae	1.9%	
Staph. aureus	1.6%	
Adenovirus	1.4%	
Legionella pneumophila	1.4%	
Enterobacteriaceae	1.4%	
Haemophilus influenzae	0.5%	
Chlamydia pneumoniae	0.4%	
Other	2.3%	
	Jair	, N Engl J Med 2015;373:415-427


























































#### Check for updates

## AMERICAN THORACIC SOCIETY DOCUMENTS

## Released May 2021

# Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia

An Official American Thoracic Society Clinical Practice Guideline

**Outpatients:** we suggest <u>not</u> performing routine NAAT testing for respiratory viral pathogens other than influenza.

**Inpatients:** we suggest performing NAAT testing for respiratory viruses other than influenza in patients with severe CAP or immunocompromised state

# **ATS/IDSA Guidelines**

# Obtain sputum gram stain & culture in inpatients if:

## Any of the following:

- the patient has severe pneumonia
- you believe empiric coverage for MRSA or Pseudomonas is necessary
- the patient has a prior history of MRSA or Pseudomonas infection
- patient was been hospitalized and received IV antibiotics within the preceding 90 days

#### Test for influenza if influenza is circulating in the community. Test for other respiratory viruses if severe pneumonia or immunocompromised.

# **My Opinion**


# Obtain sputum gram stain & culture + viral studies in <u>all</u> inpatients


## My reasons:

- Risk factors for resistant organisms are ill defined
- Positive cultures can help you tailor treatment
- Negative cultures can facilitate stopping antibiotics early
- Culture data is critical to generate hospital antibiograms to inform future empiric treatment choices
- Many viruses cause pneumonia & they circulate year-round (Covid!)
- Viral diagnosis has infection control implications





	Standard Regimen	MRSA coverage?	Pseudomonas coverage?
Mild disease	B-lactam + macrolide or Fluoroquinolone	If prior history of respiratory MRSA then cover for MRSA If risk factors alone, get cultures & nasal PCR. Only cover MRSA if cultures or nasal PCR positive	If prior history of respiratory Pseudomonas then cover for Pseudomonas If risk factors alone, get cultures. Only cover for Pseudomonas if cultures positive
Severe disease	B-lactam + (macrolide or fluroquinolone)	If prior history of respiratory MRSA or risk factors for MRSA then get cultures and cover MRSA upfront	If prior history of respiratory Pseudomonas or risk factors for Pseudomonas get cultures and cover for Pseudomonas upfront







atients with suspected VAP rand	lomized to Gram stain-guidec	d vs guideline-based empiric antibiot
	GNRs present	GNRs not seen
GPCs in clusters	Cover for MRSA & Pseudomonas	Cover for just MRSA
GPCs in chains or pairs	Cover for just Pseudomonas	Non-Pseudomonal beta lactam
GPCs not seen	Cover for just Pseudomonas	Cover for MRSA & Pseudomonas














130 patients h	JU patients with se	ere CAP randon	nized to hydrocortisone	200mg/day x 4-8d vs placebo
	Hydrocortisone Placebo		Risk difference 95%Cl	
Mechanie Yes No	cal ventilation 19 / 178 25 / 175 6 / 222 22 / 220	, <b></b>	-3.6 [-9.6 ; 2.3] -7.3 [-12.6 ; -2.0]	Bottom Line
Isolated Yes No	germ 14/211 22/227 11/189 25/168	, <b>-</b>	-3.1 [-8.4 ; 2.3] -9.1 [-15.0 ; -3.1]	Consider steroids for:
Age > 65 Yes No	years 19/222 38/228 6/178 9/167	, <u> </u>	-8.1 [-13.3 ; -2.9] -2.0 [-8.0 ; 4.0]	severe CAP (ICU)
Sex Men Women	21/281 31/271 4/119 16/124	, <b>•</b> •	-4.0 [-8.7 ; 0.8] -9.5 [-16.7 ; -2.3]	and • <24h since admission
PSI > 130 Yes No	) 22 /181 32 / 193 3 / 215 15 / 199	, —_•	-4.4 [-10.2 ; 1.3] -6.1 [-11.6 ; -0.7]	and • CRP >150mg/L
CRP > 15 Yes No	5mg/dL 10 /208 26 / 215 9 / 90 12 / 97	, <b>– – –</b> – – – – – – – – – – – – – – – –	-7.3 [-12.8 ; -1.7] -2.4 [-10.7 ; 6.0]	
All patier	nts	<b>⊢</b> −−−	-5.6 [-9.6 ;-1.7]	












































# **ATS/IDSA Guidelines**


Treat all patients for a minimum of 5 days


## **My Opinion**


If patient is immunocompetent, hemodynamically stable, and clearly improving then <5 days is fine.

## My reasons:

- Diagnosis of pneumonia is often questionable. Even when the diagnosis is correct, a third or more are caused by viruses
- 2 RCTs showing 3 days as good as 8 days for both mild and severe CAP







## Summary

- Diagnosing pneumonia is challenging. We're often wrong. CT may help.
- Many (?most) pneumonias are caused by **viruses.** Test for them.
- Tailor the urgency of treatment to severity of illness and certainty of infection. If you're on the fence and the patient is stable get more data before starting antibiotics.
- Know your antibiogram. Vancomycin not necessary for most patients.
   If you start it, stop if MRSA not found. Atypical coverage most important for patients with severe disease or compromised immune systems
- Short course regimens (3-5 days) usually adequate. Serial procalcitonin measures may enable shorter courses. Don't reset the clock at discharge!

